Biodexa Pharmaceuticals Plc (BDRX)

$0.74

-0.03

(-3.75%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $0.74
    $0.78
    $0.74
    downward going graph

    0.0%

    Downside

    Day's Volatility :4.52%

    Upside

    4.52%

    downward going graph
  • $0.67
    $9.64
    $0.74
    downward going graph

    9.46%

    Downside

    52 Weeks Volatility :93.05%

    Upside

    92.32%

    downward going graph

Returns

PeriodBiodexa Pharmaceuticals PlcIndex (Russel 2000)
3 Months
-40.69%
0.0%
6 Months
-59.63%
0.0%
1 Year
-88.21%
0.0%
3 Years
-97.95%
-20.2%

Highlights

Market Capitalization
11.4M
Book Value
$1.57
Earnings Per Share (EPS)
-10.35
Wall Street Target Price
8.0
Profit Margin
0.0%
Operating Margin TTM
-2843.37%
Return On Assets TTM
-51.38%
Return On Equity TTM
-180.59%
Revenue TTM
381.0K
Revenue Per Share TTM
0.48
Quarterly Revenue Growth YOY
-64.1%
Gross Profit TTM
-4.4M
EBITDA
-6.5M
Diluted Eps TTM
-10.35
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Biodexa Pharmaceuticals Plc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
00
Hold
1
1
3
Sell
00
00
3

Analyst Forecast

What analysts predicted

Upside of 981.08%

Current $0.74
Target $8.00

Company Financials

FY18Y/Y Change
Revenue
1.9M
↑ 95.96%
Net Income
-10.4M
↓ 11.42%
Net Profit Margin
-534.98%
↑ 648.54%
FY19Y/Y Change
Revenue
883.8K
↓ 65.22%
Net Income
-12.0M
↓ 11.86%
Net Profit Margin
-1.4K%
↓ 820.81%
FY20Y/Y Change
Revenue
467.6K
↓ 49.11%
Net Income
-30.2M
↑ 142.82%
Net Profit Margin
-6.5K%
↓ 5113.31%
FY21Y/Y Change
Revenue
780.2K
↑ 68.51%
Net Income
-7.4M
↓ 75.39%
Net Profit Margin
-944.64%
↑ 5524.46%
FY22Y/Y Change
Revenue
699.0K
↑ 20.93%
Net Income
-7.7M
↑ 40.22%
Net Profit Margin
-1.1K%
↓ 150.64%
FY23Y/Y Change
Revenue
485.1K
↓ 45.49%
Net Income
-9.0M
↓ 7.54%
Net Profit Margin
-1.9K%
↓ 762.73%
Q3 FY22Q/Q Change
Revenue
129.0K
↓ 50.64%
Net Income
-2.6M
↑ 50.11%
Net Profit Margin
-2.0K%
↓ 1335.12%
Q4 FY22Q/Q Change
Revenue
115.5K
↑ 0.0%
Net Income
-2.3M
↑ 0.0%
Net Profit Margin
-2.0K%
↑ 0.0%
Q1 FY23Q/Q Change
Revenue
184.6K
↑ 29.0%
Net Income
-2.2M
↓ 22.35%
Net Profit Margin
-1.2K%
↑ 791.86%
Q2 FY23Q/Q Change
Revenue
188.0K
↑ 0.0%
Net Income
-2.3M
↑ 0.0%
Net Profit Margin
-1.2K%
↑ 0.0%
Q3 FY23Q/Q Change
Revenue
41.5K
↓ 72.15%
Net Income
-1.8M
↓ 1.6%
Net Profit Margin
-4.2K%
↓ 3032.8%
Q4 FY23Q/Q Change
Revenue
41.5K
↑ 0.0%
Net Income
-1.8M
↑ 0.0%
Net Profit Margin
-4.2K%
↑ 0.0%
FY18Y/Y Change
Total Assets
20.4M
↓ 58.47%
Total Liabilities
3.5M
↓ 75.8%
FY19Y/Y Change
Total Assets
40.5M
↑ 51.12%
Total Liabilities
14.9M
↑ 222.07%
FY20Y/Y Change
Total Assets
13.4M
↓ 68.22%
Total Liabilities
4.2M
↓ 72.66%
FY21Y/Y Change
Total Assets
17.4M
↑ 31.54%
Total Liabilities
3.3M
↓ 20.6%
FY22Y/Y Change
Total Assets
5.5M
↓ 57.21%
Total Liabilities
2.4M
↓ 3.96%
FY23Y/Y Change
Total Assets
13.4M
↑ 90.81%
Total Liabilities
7.5M
↑ 148.16%
Q3 FY22Q/Q Change
Total Assets
5.5M
↓ 42.94%
Total Liabilities
2.4M
↑ 7.85%
Q4 FY22Q/Q Change
Total Assets
5.5M
↑ 0.0%
Total Liabilities
2.4M
↑ 0.0%
Q1 FY23Q/Q Change
Total Assets
9.9M
↑ 44.11%
Total Liabilities
3.3M
↑ 12.7%
Q2 FY23Q/Q Change
Total Assets
10.0M
↑ 0.0%
Total Liabilities
3.4M
↓ 0.01%
Q3 FY23Q/Q Change
Total Assets
10.5M
↑ 32.4%
Total Liabilities
5.9M
↑ 120.23%
Q4 FY23Q/Q Change
Total Assets
13.4M
↑ 0.0%
Total Liabilities
7.5M
↑ 0.0%
FY19Y/Y Change
Operating Cash Flow
-8.5M
↓ 51.75%
Investing Cash Flow
-5.0M
-
Financing Cash Flow
24.6M
↓ 389.45%
FY20Y/Y Change
Operating Cash Flow
-12.7M
↑ 43.33%
Investing Cash Flow
3.5M
↓ 167.61%
Financing Cash Flow
4.2M
↓ 83.54%
FY21Y/Y Change
Operating Cash Flow
-8.1M
↓ 35.4%
Investing Cash Flow
-375.3K
↓ 110.8%
Financing Cash Flow
11.9M
↑ 185.51%
Q3 FY22Q/Q Change
Operating Cash Flow
-2.0M
↓ 0.85%
Investing Cash Flow
11.2K
-
Financing Cash Flow
69.8K
↓ 260.26%
Q4 FY22Q/Q Change
Operating Cash Flow
-1.8M
↑ 0.0%
Investing Cash Flow
10.0K
↑ 0.0%
Financing Cash Flow
62.5K
↑ 0.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.4M
↑ 10.6%
Investing Cash Flow
12.4K
↑ 0.0%
Financing Cash Flow
3.9M
↑ 4901.6%
Q2 FY23Q/Q Change
Operating Cash Flow
-2.4M
↑ 0.0%
Investing Cash Flow
12.6K
↑ 0.0%
Financing Cash Flow
3.9M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Biodexa Pharmaceuticals Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc
-8.44%
-59.63%
-88.21%
-97.95%
-97.95%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc
NA
NA
NA
0.0
-1.81
-0.51
NA
1.57
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc
Buy
$11.4M
-97.95%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Biodexa Pharmaceuticals Plc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 149.0K → 41.5K (in $), with an average decrease of 36.1% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 5 quarters, -2.29M → -1.75M (in $), with an average increase of 7.6% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 149.8%

Company Information

midatech is a world leader in the design, synthesis and manufacture of biocompatible gold nanoparticles (gnps) with a core focus on therapeutics for diabetes and cancer. midatech has a strong pipeline of product candidates in clinical and pre-clinical development for the treatment of diabetes and various cancers. in 2012, midatech established midasol therapeutics lp, a strategic joint venture with monosol rx llc to focus on the development and commercialization, via partnering or licensing, of products primarily for the treatment of diabetes. midasol’s lead product, midaform™ insulin pharmfilm, is a unique product for the oral delivery of insulin in diabetic patients and will enter phase ii clinical studies in 2014. these technologies are also being evaluated in the diabetes area by a major us pharmaceutical company. midatech’s unique gnp technology enables the administration and targeted delivery of therapeutic compounds to specific cells and tissues. multiple drug molecules can b

Organization
Biodexa Pharmaceuticals Plc
Employees
21
CEO
Mr. Stephen A. Stamp
Industry
Miscellaneous

Discover More

FAQs